Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study.

COVID-19 cell biology drug repurposing medicine metabolic regulation translational research viruses

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
27 01 2023
Historique:
received: 03 05 2022
accepted: 26 01 2023
pubmed: 28 1 2023
medline: 22 2 2023
entrez: 27 1 2023
Statut: epublish

Résumé

Viral infection is associated with a significant rewire of the host metabolic pathways, presenting attractive metabolic targets for intervention. We chart the metabolic response of lung epithelial cells to SARS-CoV-2 infection in primary cultures and COVID-19 patient samples and perform in vitro metabolism-focused drug screen on primary lung epithelial cells infected with different strains of the virus. We perform observational analysis of Israeli patients hospitalized due to COVID-19 and comparative epidemiological analysis from cohorts in Italy and the Veteran's Health Administration in the United States. In addition, we perform a prospective non-randomized interventional open-label study in which 15 patients hospitalized with severe COVID-19 were given 145 mg/day of nanocrystallized fenofibrate added to the standard of care. SARS-CoV-2 infection produced transcriptional changes associated with increased glycolysis and lipid accumulation. Metabolism-focused drug screen showed that fenofibrate reversed lipid accumulation and blocked SARS-CoV-2 replication through a PPARα-dependent mechanism in both alpha and delta variants. Analysis of 3233 Israeli patients hospitalized due to COVID-19 supported in vitro findings. Patients taking fibrates showed significantly lower markers of immunoinflammation and faster recovery. Additional corroboration was received by comparative epidemiological analysis from cohorts in Europe and the United States. A subsequent prospective non-randomized interventional open-label study was carried out on 15 patients hospitalized with severe COVID-19. The patients were treated with 145 mg/day of nanocrystallized fenofibrate in addition to standard-of-care. Patients receiving fenofibrate demonstrated a rapid reduction in inflammation and a significantly faster recovery compared to patients admitted during the same period. Taken together, our data suggest that pharmacological modulation of PPARα should be strongly considered as a potential therapeutic approach for SARS-CoV-2 infection and emphasizes the need to complete the study of fenofibrate in large randomized controlled clinical trials. Funding was provided by European Research Council Consolidator Grants OCLD (project no. 681870) and generous gifts from the Nikoh Foundation and the Sam and Rina Frankel Foundation (YN). The interventional study was supported by Abbott (project FENOC0003). NCT04661930.

Sections du résumé

Background
Viral infection is associated with a significant rewire of the host metabolic pathways, presenting attractive metabolic targets for intervention.
Methods
We chart the metabolic response of lung epithelial cells to SARS-CoV-2 infection in primary cultures and COVID-19 patient samples and perform in vitro metabolism-focused drug screen on primary lung epithelial cells infected with different strains of the virus. We perform observational analysis of Israeli patients hospitalized due to COVID-19 and comparative epidemiological analysis from cohorts in Italy and the Veteran's Health Administration in the United States. In addition, we perform a prospective non-randomized interventional open-label study in which 15 patients hospitalized with severe COVID-19 were given 145 mg/day of nanocrystallized fenofibrate added to the standard of care.
Results
SARS-CoV-2 infection produced transcriptional changes associated with increased glycolysis and lipid accumulation. Metabolism-focused drug screen showed that fenofibrate reversed lipid accumulation and blocked SARS-CoV-2 replication through a PPARα-dependent mechanism in both alpha and delta variants. Analysis of 3233 Israeli patients hospitalized due to COVID-19 supported in vitro findings. Patients taking fibrates showed significantly lower markers of immunoinflammation and faster recovery. Additional corroboration was received by comparative epidemiological analysis from cohorts in Europe and the United States. A subsequent prospective non-randomized interventional open-label study was carried out on 15 patients hospitalized with severe COVID-19. The patients were treated with 145 mg/day of nanocrystallized fenofibrate in addition to standard-of-care. Patients receiving fenofibrate demonstrated a rapid reduction in inflammation and a significantly faster recovery compared to patients admitted during the same period.
Conclusions
Taken together, our data suggest that pharmacological modulation of PPARα should be strongly considered as a potential therapeutic approach for SARS-CoV-2 infection and emphasizes the need to complete the study of fenofibrate in large randomized controlled clinical trials.
Funding
Funding was provided by European Research Council Consolidator Grants OCLD (project no. 681870) and generous gifts from the Nikoh Foundation and the Sam and Rina Frankel Foundation (YN). The interventional study was supported by Abbott (project FENOC0003).
Clinical trial number
NCT04661930.

Identifiants

pubmed: 36705566
doi: 10.7554/eLife.79946
pii: 79946
pmc: PMC9937660
doi:
pii:

Substances chimiques

Fenofibrate U202363UOS
Lipids 0
PPAR alpha 0

Banques de données

GEO
['GSE147507', 'GSE145926', 'GSE153970']
ClinicalTrials.gov
['NCT04661930']

Types de publication

Clinical Trial Journal Article Observational Study Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Research Council
ID : 681870
Pays : International
Organisme : NHLBI NIH HHS
ID : R01 HL157108
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG074989
Pays : United States

Informations de copyright

© 2023, Ehrlich et al.

Déclaration de conflit d'intérêts

AE is registered as an investor in a PCT regarding the use of metabolic regulators for COVID. The author has a patent on the use of PPAR agonists to treat COVID. The author has no other competing interests to declare, KI, MN, IA, YD, NA, LK, NR, MH, SS, IH, CP, MC, AG, AB, MM, SM No competing interests declared, AC has received personal honoraria for statistical consultation from Recipharm, and personal honoraria for manuscript writing from both Sharper Srl and Fidia Pharmaceuticals. The author has no other competing interests to declare, CS is President of Fondazione (totally supported by family). The author has no other competing interests to declare, JC received funding from National Institutes of Health (1R01HL157108-01A1,1R01AG074989-01) . The author has no other competing interests to declare, JC has received consulting honoraria from Sanifit, Bristol Myers Squibb, Merck, Edwards Lifesciences, Bayer, JNJ, Fukuda-Denshi, NGM Bio, Mayo institute of technology and the University of Delaware, and research grants from the National Institutes of Health, Abbott, Microsoft, Fukuda-Denshi and Bristol Myers Squibb. He has received compensation from the American Heart Association and the American College of Cardiology for editorial roles, and visiting speaker honoraria from Washington University, Emory University, University of Utah, the Japanese Association for Cardiovascular Nursing and the Korean Society of Cardiology. The author is named as inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of Heart Failure and Preserved Ejection Fraction and for the use of biomarkers in heart failure with preserved ejection fraction. The author has participated on the Advisory board for Bristol-Myers Squibb Data safety monitoring board for studies by the University of Delaware and UT Southwestern, and is Vice President of North American Artery Society. The author has received research device loans from Atcor Medical, Fukuda-Denshi, Unex, Uscom, NDD Medical Technologies, Microsoft, and MicroVision Medical. The author has no other competing interests to declare, LD is affiliated with BioStats Statistical Consulting Ltd where they work as a Biostatistician. The authors has received payment for statistical work for the manuscript and consulting fees from Tissue Dynamics Ltd. The author has no other competing interests to declare, OS has received consulting honoraria from Sanofi, Roche and Neopharm, and lectures honoraria from Roche . He is the chairmen of the Israel Association for the study of the liver. The author has no other competing interests to declare, YN is registered as an investor in a PCT regarding the use of metabolic regulators for COVID and has a patent on the use of PPAR agonists to treat COVID. The author has no other competing interests to declare

Références

Biochim Biophys Acta. 2001 Oct 31;1533(3):220-32
pubmed: 11731332
JCI Insight. 2020 Jul 23;5(14):
pubmed: 32559180
Nat Med. 2013 May;19(5):557-66
pubmed: 23652116
Atherosclerosis. 2015 Jun;240(2):389-97
pubmed: 25881202
Cell Metab. 2020 Aug 4;32(2):176-187.e4
pubmed: 32592657
Arterioscler Thromb Vasc Biol. 2010 May;30(5):894-9
pubmed: 20393155
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
Cell Rep. 2017 May 23;19(8):1640-1653
pubmed: 28538182
Acta Diabetol. 2010 Sep;47(3):193-9
pubmed: 19333547
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Am J Transl Res. 2020 Oct 15;12(10):6646-6654
pubmed: 33194061
Science. 2019 Dec 20;366(6472):
pubmed: 31857451
Int J Mol Sci. 2020 Nov 16;21(22):
pubmed: 33207699
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Biometrics. 2001 Mar;57(1):114-9
pubmed: 11252585
Health Serv Res. 2016 Oct;51(5):1960-80
pubmed: 26841379
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Am J Physiol Cell Physiol. 2021 Jan 1;320(1):C57-C65
pubmed: 33151090
Arzneimittelforschung. 2002;52(3):200-4
pubmed: 11963648
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Cell Rep Med. 2020 Nov 17;1(8):100144
pubmed: 33163981
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Eur J Nucl Med Mol Imaging. 2020 Jul;47(7):1649-1656
pubmed: 32342191
Front Med (Lausanne). 2020 Jun 09;7:301
pubmed: 32582743
Cell Host Microbe. 2020 Sep 9;28(3):402-410.e5
pubmed: 32544461
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
EMBO Rep. 2005 Jul;6 Spec No:S39-44
pubmed: 15995660
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Feb;1863(2):143-151
pubmed: 29155055
J Biol Chem. 2012 Mar 23;287(13):10099-10114
pubmed: 22267724
Front Pharmacol. 2019 Sep 18;10:973
pubmed: 31619986
Pharmacotherapy. 2008 May;28(5):570-5
pubmed: 18447655
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
J Invest Dermatol. 2002 Jan;118(1):94-101
pubmed: 11851881
Atherosclerosis. 2021 Dec;339:55-56
pubmed: 34802683
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
J Cheminform. 2019 Feb 14;11(1):15
pubmed: 30767155
Mol Cell Proteomics. 2008 Oct;7(10):2019-27
pubmed: 18669619
Front Immunol. 2019 Jul 03;10:1533
pubmed: 31333664
Cell Rep. 2021 Aug 3;36(5):109479
pubmed: 34320401
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
BMC Bioinformatics. 2013 Aug 21;14:254
pubmed: 23965047
Cell Metab. 2020 Oct 6;32(4):537-547.e3
pubmed: 32861268
J Virol. 2020 Sep 15;94(19):
pubmed: 32699094
JAMA Netw Open. 2020 Dec 1;3(12):e2029058
pubmed: 33301018
Cell Rep Med. 2020 Jul 21;1(4):100059
pubmed: 32835306
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Cell Metab. 2020 Sep 1;32(3):437-446.e5
pubmed: 32697943
Mol Cell Biochem. 2010 Dec;345(1-2):197-206
pubmed: 20740305
BMC Infect Dis. 2021 Mar 24;21(1):299
pubmed: 33761881
PLoS Pathog. 2013;9(4):e1003266
pubmed: 23592989
Journ Annu Diabetol Hotel Dieu. 2001;:23-32
pubmed: 11565466
J Lipid Res. 2016 Aug;57(8):1329-38
pubmed: 27146479
Viruses. 2019 Jan 16;11(1):
pubmed: 30654597
Nat Protoc. 2015 Jun;10(6):823-44
pubmed: 25950236
Drugs Today (Barc). 2006 Jan;42(1):39-64
pubmed: 16511610
Dev Cell. 2008 Dec;15(6):829-40
pubmed: 19081072
Hepatology. 2006 Jul;44(1):117-25
pubmed: 16799963
Sci Rep. 2021 Mar 30;11(1):7217
pubmed: 33785815
Oncol Rep. 2018 Apr;39(4):1957-1965
pubmed: 29484415
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nat Commun. 2021 Jun 3;12(1):3309
pubmed: 34083527
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31550243
Nat Commun. 2019 Jan 10;10(1):120
pubmed: 30631056
Am J Med. 1987 Nov 27;83(5B):21-5
pubmed: 3318449
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2031-2038
pubmed: 33113469
Nat Chem Biol. 2016 Dec;12(12):1037-1045
pubmed: 27723751
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
Sci Rep. 2017 Aug 22;7(1):9110
pubmed: 28831119
Nat Commun. 2020 Aug 6;11(1):3910
pubmed: 32764693
Cancer Metab. 2014 Aug 28;2:12
pubmed: 25184038
Cardiol Res. 2013 Apr;4(2):47-55
pubmed: 28352420
Eur J Pharmacol. 2016 Apr 5;776:106-15
pubmed: 26879867
Front Genet. 2021 Mar 16;12:599261
pubmed: 33796130
Nature. 2021 Oct;598(7882):E2
pubmed: 34625743
Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):E7158-E7165
pubmed: 29987044
Thorax. 2011 May;66(5):383-8
pubmed: 21325145
Viruses. 2021 Feb 27;13(3):
pubmed: 33673614
Sci Rep. 2020 Nov 10;10(1):19395
pubmed: 33173052
J Biol Chem. 2013 Jun 28;288(26):18707-15
pubmed: 23696639
Pathogens. 2021 Apr 23;10(5):
pubmed: 33922476
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E485-93
pubmed: 17003244
J Biol Chem. 2017 Apr 28;292(17):7189-7207
pubmed: 28270511
Sci Adv. 2021 Jul 28;7(31):
pubmed: 34321199
JAMA. 2021 May 25;325(20):2115-2116
pubmed: 33830171
Br J Pharmacol. 2009 Oct;158(4):994-1003
pubmed: 19703165
Oncotarget. 2017 Jul 31;8(47):82491-82505
pubmed: 29137280
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
Nat Rev Endocrinol. 2020 Jun;16(6):297-298
pubmed: 32242089
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
Nature. 2021 Jul;595(7865):107-113
pubmed: 33915569
Clin Ther. 2011 Jun;33(6):766-75
pubmed: 21704241
Virology. 2010 Sep 15;405(1):139-48
pubmed: 20580052
Pharm Stat. 2021 Jan;20(1):15-24
pubmed: 32776719
Int J Infect Dis. 2020 Jun;95:332-339
pubmed: 32334118
Nature. 2020 Jul;583(7816):469-472
pubmed: 32408336
Front Pharmacol. 2021 Aug 06;12:660490
pubmed: 34421587
J Viral Hepat. 2006 Jul;13(7):441-8
pubmed: 16792537
Lab Chip. 2018 Aug 21;18(17):2510-2522
pubmed: 29992215
Cardiovasc Drugs Ther. 2012 Apr;26(2):95-9
pubmed: 22274300
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
J Nutr. 2005 Nov;135(11):2499-502
pubmed: 16251600
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1951-6
pubmed: 24449882
Nature. 2020 Oct;586(7827):113-119
pubmed: 32707573
Nature. 1959 Jan 24;183(4656):271-2
pubmed: 13622777

Auteurs

Avner Ehrlich (A)

Grass Center for Bioengineering, Benin School of Computer Science and Engineering, Jerusalem, Israel.
Department of Cell and Developmental Biology, Silberman Institute of Life Sciences, Jerusalem, Israel.

Konstantinos Ioannidis (K)

Grass Center for Bioengineering, Benin School of Computer Science and Engineering, Jerusalem, Israel.
Department of Cell and Developmental Biology, Silberman Institute of Life Sciences, Jerusalem, Israel.

Makram Nasar (M)

Division of Infectious Diseases, Barzilai Medical Center, Ashkelon, Israel.

Ismaeel Abu Alkian (I)

Division of Infectious Diseases, Barzilai Medical Center, Ashkelon, Israel.

Yuval Daskal (Y)

Grass Center for Bioengineering, Benin School of Computer Science and Engineering, Jerusalem, Israel.
Department of Cell and Developmental Biology, Silberman Institute of Life Sciences, Jerusalem, Israel.

Nofar Atari (N)

Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Tel Hashomer, Israel.

Limor Kliker (L)

Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Tel Hashomer, Israel.

Nir Rainy (N)

Laboratory Division, Shamir (Assaf Harofeh) Medical Center, Zerifin, Italy.

Matan Hofree (M)

Klarman Cell Observatory, The Broad Institute of Harvard and MIT, Cambridge, United States.

Sigal Shafran Tikva (S)

Laboratory Division, Shamir (Assaf Harofeh) Medical Center, Zerifin, Italy.
Hadassah Research and Innovation Center, Jerusalem, Israel.
Department of Nursing, Faculty of School of Life and Health Sciences, The Jerusalem College of Technology Lev Academic Center, Jerusalem, Israel.

Inbal Houri (I)

Department of Gastroenterology, Sourasky Medical Center, Tel Aviv, Israel.

Arrigo Cicero (A)

IRCSS S.Orsola-Malpighi University Hospital, Bologna, Italy.

Chiara Pavanello (C)

Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.
Centro Dislipidemie, Niguarda Hospital, Milano, Italy.

Cesare R Sirtori (CR)

Centro Dislipidemie, Niguarda Hospital, Milano, Italy.

Jordana B Cohen (JB)

Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.

Julio A Chirinos (JA)

Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.

Lisa Deutsch (L)

BioStats Statistical Consulting Ltd, Modiin, Israel.

Merav Cohen (M)

Grass Center for Bioengineering, Benin School of Computer Science and Engineering, Jerusalem, Israel.
Department of Cell and Developmental Biology, Silberman Institute of Life Sciences, Jerusalem, Israel.

Amichai Gottlieb (A)

Division of Infectious Diseases, Barzilai Medical Center, Ashkelon, Israel.

Adina Bar-Chaim (A)

Laboratory Division, Shamir (Assaf Harofeh) Medical Center, Zerifin, Italy.

Oren Shibolet (O)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Michal Mandelboim (M)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Shlomo L Maayan (SL)

Division of Infectious Diseases, Barzilai Medical Center, Ashkelon, Israel.

Yaakov Nahmias (Y)

Grass Center for Bioengineering, Benin School of Computer Science and Engineering, Jerusalem, Israel.
Department of Cell and Developmental Biology, Silberman Institute of Life Sciences, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH